London, UK, 23 March 2026 - Persica Pharmaceuticals Limited (Persica), a clinical stage biotechnology company developing a transformative treatment for chronic Low Back Pain (cLBP), today announces ...
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has convened the Annual General Meeting of Shareholders (AGM) 2026 and published the agenda with ...
Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery and development of non-cereblon/non-VHL Targeted Glue™ ...
Rakovina Therapeutics Inc. (TSX-V: RKV)(FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to ...
Additional funding of €4m from new co-lead investor Biovance Capital, and €1.5m from existing co-lead Kurma Partners, to reach a total of €5.5m. Funds will be used to further develop Laigo’s ...
BASEL, Switzerland, March 23, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage preclinical biotech focused on reprogramming the immune system with precision biologics, announces today the appointment of ...
A new research project aims to develop the world’s first therapy to eliminate and prevent the spread of a toxic brain protein that drives Parkinson’s disease. Innovation Fund Denmark has invested DKK ...
Philips proposes new appointment and re-appointments to its Supervisory Board and CEO re-appointment
John DeFord proposed as new member of the Supervisory Board. Paul Stoffels, Herna Verhagen and Sanjay Poonen proposed for re-appointment as members of the Supervisory Board. Marc Harrison will step ...
Pourquoi certains patients parviennent à contrôler naturellement le VIH même après l'arrêt du traitement ? Cette équipe de ...
Presented by CEO Dave Marver, the webcast will be held at 2:00 p.m. CEST / 08:00 a.m. ET. To join the session, please register using this link.
CoaguSense, Inc., a leading developer of point-of-care coagulation monitoring systems and a subsidiary of i-SENS, Inc. (KOSDAQ: 099190), today announced it has entered into a definitive asset purchase ...
Basel, March 23, 2026 – Novartis will present data from more than 20 abstracts from its growing immunology portfolio at this year’s American Academy of Dermatology (AAD) Annual Meeting.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results